Jessica G.
- Country
- France
- Department
- Oncologie
Research Overview
- Randomized, Double-Blind Phase 3b Study of Nivolumab Plus Ipilimumab Versus Nivolumab Monotherapy in Untreated Advanced Renal Cell Carcinoma with Intermediate or Poor Risk
- Phase 3 Randomized Study of Elacestrant Versus Standard Endocrine Therapy in Node-Positive, ER-Positive, HER2-Negative Early Breast Cancer with High Recurrence Risk
- Evaluation of Gene Expression-Driven Adjuvant Chemotherapy Versus Standard Care in Premenopausal HR-Positive/HER2-Negative Breast Cancer Using Paclitaxel and Drug Combination
Data & Insights
Has run more than one trial at 47 of 294 partner sites.
Specializations
Oncology Focus
Specializes in advanced therapeutic approaches for renal cell carcinoma, with particular emphasis on cases presenting with intermediate to poor-risk factors.
- Advanced kidney cancer treatment
- Risk-stratified therapeutic approaches
- Renal oncology
Investigates innovative treatment strategies for complex renal malignancies.
Immunotherapy Expertise
Focuses on combination immunotherapy approaches in the treatment of advanced kidney cancer, exploring both monotherapy and combination treatment protocols.
- Immunological treatment strategies
- Combined therapeutic modalities
- Novel treatment protocols
Evaluates therapeutic responses in advanced renal malignancies using established clinical criteria.
Clinical Assessment
Specializes in evaluating treatment outcomes and response rates in advanced kidney cancer patients using standardized assessment criteria.
- Response evaluation
- Progressive disease monitoring
- Clinical outcomes assessment
Implements systematic approaches to measure therapeutic efficacy in renal cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.